NCT05726370 2025-06-22
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
Dana-Farber Cancer Institute
UNICANCER
Second Affiliated Hospital, School of Medicine, Zhejiang University
Medical Oncology & Hematology Associates of Northern Virginia